JPMorgan analyst Chris Schott upgraded Regeneron to Overweight from Neutral with an $850 price target ahead of a number of important catalysts he expects in 2023. He remains above consensus and sees upside to Street estimates for Dupixent, while he sees 8mg Eylea as a " best in class therapy" that can meaningfully extend Regeneron’s U.S. AMD franchise, Schott tells investors.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Piper ‘at a loss’ to explain Regeneron Q4 miss for Eylea
- Regeneron sees about $1.5B in Q4 U.S. net product sales of Eylea
- FDA Dermatologic & Ophthalmic Drugs Advisory Committee Virtual Meeting
- 2seventy Bio announces amendment to collaboration with Regeneron
- CytomX Therapeutics updates business, announces 2023 relationship with Moderna
